Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.

Literature DB >> 6123344

Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.

P Dayer, A Kubli, A Kupfer, F Courvoisier, L Balant, J Fabre.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1982 PMID： 6123344 PMCID： PMC1402093 DOI： 10.1111/j.1365-2125.1982.tb01453.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

14 in total

1. [Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality].

Authors: L Balant; A Gorgia; J M Tschopp; C Revillard; J Fabre
Journal: Schweiz Med Wochenschr Date: 1976-10-09

2. Polymorphism of carbon oxidation of drugs and clinical implications.

Authors: T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal: Br Med J Date: 1978-09-02

3. [Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol].

Authors: J M Tschopp; A Gorgia; L Balant; C Revillard; R J Francis; F J Fabre
Journal: Schweiz Med Wochenschr Date: 1978-05-20

4. [Pharmacokinetics of bufuralol in man].

Authors: L Balant; R J Francis; J M Tschopp; D Tinguely; J Estreicher; J Fabre
Journal: Pharm Acta Helv Date: 1978

5. Polymorphism in drug metabolism.

Authors: L Balant; P Dayer; J Fabre
Journal: Br Med J Date: 1978-11-04

6. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

Authors: L Bertilsson; H J Dengler; M Eichelbaum; H U Schulz
Journal: Eur J Clin Pharmacol Date: 1980-02 Impact factor: 2.953

7. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors: D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal: J Med Genet Date: 1980-04 Impact factor: 6.318

8. Determined of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection.

Authors: R J Francis; P B East; S J McLaren; J Larman
Journal: Biomed Mass Spectrom Date: 1976-12

9. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors: M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal: Eur J Clin Pharmacol Date: 1979-09 Impact factor: 2.953

10. Polymorphic hydroxylation of Debrisoquine in man.

Authors: A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal: Lancet Date: 1977-09-17 Impact factor: 79.321

14 in total

1. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.

Authors: P Dayer; L Balant; A Küpfer; F Courvoisier; J Fabre
Journal: Eur J Clin Pharmacol Date: 1983 Impact factor: 2.953

2. Phenotyping polymorphic drug metabolism in the French Caucasian population.

Authors: E Jacqz; H Dulac; H Mathieu
Journal: Eur J Clin Pharmacol Date: 1988 Impact factor: 2.953

3. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.

Authors: P Dayer; T Leemann; A Marmy; J Rosenthaler
Journal: Eur J Clin Pharmacol Date: 1985 Impact factor: 2.953

Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.

1. [Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality].

2. Polymorphism of carbon oxidation of drugs and clinical implications.

3. [Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol].

4. [Pharmacokinetics of bufuralol in man].

5. Polymorphism in drug metabolism.

6. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

7. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

8. Determined of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection.

9. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

10. Polymorphic hydroxylation of Debrisoquine in man.

1. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.

2. Phenotyping polymorphic drug metabolism in the French Caucasian population.

3. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.

4. Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.

Review 5. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Review 6. Oxidation phenotype and the metabolism and action of beta-blockers.

Review 7. Clinical significance of genetic influences on cardiovascular drug metabolism.

8. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

9. The genetic control of bufuralol metabolism in man.

10. Polymorphic metabolism of beta-adrenoceptor antagonists.